Profound Medical Corp Stock Analysis
PROF Stock | USD 8.12 0.03 0.37% |
Profound Medical Corp is undervalued with Real Value of 10.29 and Target Price of 16.82. The main objective of Profound Medical stock analysis is to determine its intrinsic value, which is an estimate of what Profound Medical Corp is worth, separate from its market price. There are two main types of Profound Medical's stock analysis: fundamental analysis and technical analysis.
The Profound Medical stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Profound Medical's ongoing operational relationships across important fundamental and technical indicators.
Profound |
Profound Stock Analysis Notes
About 44.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.34. Profound Medical Corp last dividend was issued on the 16th of October 2019. The entity had 1:10 split on the 16th of October 2019. Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada. Profound Medical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 146 people. To find out more about Profound Medical Corp contact Arun MBA at 647 476 1350 or learn more at https://www.profoundmedical.com.Profound Medical Quarterly Total Revenue |
|
Profound Medical Corp Investment Alerts
Profound Medical generated a negative expected return over the last 90 days | |
Profound Medical has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 7.2 M. Net Loss for the year was (29.09 M) with profit before overhead, payroll, taxes, and interest of 3.02 M. | |
Profound Medical Corp currently holds about 46.21 M in cash with (22.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21. | |
Profound Medical has a frail financial position based on the latest SEC disclosures | |
Latest headline from gurufocus.com: Profound Medical to Unveil Next TULSA-AI Module, UA Alignment |
Profound Medical Corp Upcoming and Recent Events
5th of March 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
5th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Profound Largest EPS Surprises
Earnings surprises can significantly impact Profound Medical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2017-08-23 | 2017-06-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2016-11-16 | 2016-09-30 | -0.08 | -0.1 | -0.02 | 25 | ||
2016-05-06 | 2016-03-31 | -0.07 | -0.1 | -0.03 | 42 |
Profound Medical Environmental, Social, and Governance (ESG) Scores
Profound Medical's ESG score is a quantitative measure that evaluates Profound Medical's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Profound Medical's operations that may have significant financial implications and affect Profound Medical's stock price as well as guide investors towards more socially responsible investments.
Profound Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Bleichroeder Lp | 2024-09-30 | 133.3 K | Td Asset Management Inc | 2024-09-30 | 124.3 K | Thompson Davis & Co Inc | 2024-09-30 | 101.9 K | Renaissance Technologies Corp | 2024-09-30 | 58.9 K | K2 Principal Fund Lp | 2024-09-30 | 50 K | Chilton Investment Company, Inc. | 2024-09-30 | 45 K | Raymond James & Associates | 2024-09-30 | 43 K | Citadel Advisors Llc | 2024-09-30 | 26.9 K | Northwest & Ethical Investments L.p. | 2024-09-30 | 23.7 K | Fidelity International Ltd | 2024-06-30 | 1.5 M | Gagnon Securities Llc | 2024-09-30 | 1.5 M |
Profound Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 200.25 M.Profound Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.66) | (0.69) | |
Return On Capital Employed | (0.76) | (0.80) | |
Return On Assets | (0.65) | (0.68) | |
Return On Equity | (0.92) | (0.96) |
Management Efficiency
Profound Medical Corp has return on total asset (ROA) of (0.4462) % which means that it has lost $0.4462 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9017) %, meaning that it created substantial loss on money invested by shareholders. Profound Medical's management efficiency ratios could be used to measure how well Profound Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.69. The current Return On Capital Employed is estimated to decrease to -0.8. At this time, Profound Medical's Total Assets are most likely to increase significantly in the upcoming years. The Profound Medical's current Other Current Assets is estimated to increase to about 1.7 M, while Non Current Assets Total are projected to decrease to roughly 1.9 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 1.47 | 1.40 | |
Tangible Book Value Per Share | 1.45 | 1.38 | |
Enterprise Value Over EBITDA | (5.94) | (6.23) | |
Price Book Value Ratio | 5.69 | 3.51 | |
Enterprise Value Multiple | (5.94) | (6.23) | |
Price Fair Value | 5.69 | 3.51 | |
Enterprise Value | 159 M | 206.9 M |
The management team at Profound Medical has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Operating Margin (3.17) | Beta 0.83 | Return On Assets (0.45) | Return On Equity (0.90) |
Technical Drivers
As of the 1st of December, Profound Medical holds the Risk Adjusted Performance of (0.02), coefficient of variation of (2,793), and Variance of 9.82. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Profound Medical, as well as the relationship between them. Please check Profound Medical Corp market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Profound Medical Corp is priced some-what accurately, providing market reflects its current price of 8.12 per share. Given that Profound Medical has information ratio of (0.08), we recommend you to check out Profound Medical Corp's recent market performance to make sure the company can sustain itself at a future point.Profound Medical Corp Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Profound Medical middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Profound Medical Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Profound Medical Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Profound Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Profound Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Profound Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hofer Michael over a month ago Acquisition by Hofer Michael of 500000 shares of Profound Medical at 0.0014 subject to Rule 16b-3 |
Profound Medical Outstanding Bonds
Profound Medical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Profound Medical Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Profound bonds can be classified according to their maturity, which is the date when Profound Medical Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Profound Medical Predictive Daily Indicators
Profound Medical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Profound Medical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Profound Medical Corporate Filings
6K | 26th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
6K | 7th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 4th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 17th of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 16th of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
11th of October 2024 Other Reports | ViewVerify | |
6K | 16th of September 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Profound Medical Forecast Models
Profound Medical's time-series forecasting models are one of many Profound Medical's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Profound Medical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Profound Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Profound Medical prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Profound shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Profound Medical. By using and applying Profound Stock analysis, traders can create a robust methodology for identifying Profound entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (3.99) | (4.19) | |
Operating Profit Margin | (3.97) | (4.17) | |
Net Loss | (3.97) | (4.17) | |
Gross Profit Margin | 0.61 | 0.37 |
Current Profound Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Profound analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Profound analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
16.82 | Strong Buy | 6 | Odds |
Most Profound analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Profound stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Profound Medical Corp, talking to its executives and customers, or listening to Profound conference calls.
Profound Stock Analysis Indicators
Profound Medical Corp stock analysis indicators help investors evaluate how Profound Medical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Profound Medical shares will generate the highest return on investment. By understating and applying Profound Medical stock analysis, traders can identify Profound Medical position entry and exit signals to maximize returns.
Begin Period Cash Flow | 46.5 M | |
Long Term Debt | 5 M | |
Common Stock Shares Outstanding | 21.2 M | |
Total Stockholder Equity | 31.2 M | |
Tax Provision | -128 K | |
Property Plant And Equipment Net | 1.5 M | |
Cash And Short Term Investments | 26.1 M | |
Cash | 26.2 M | |
Accounts Payable | 3.3 M | |
Net Debt | -18.3 M | |
50 Day M A | 7.7656 | |
Total Current Liabilities | 6.4 M | |
Other Operating Expenses | 35.8 M | |
Non Current Assets Total | 2 M | |
Non Currrent Assets Other | -2507.00 | |
Stock Based Compensation | 3.4 M |
Complementary Tools for Profound Stock analysis
When running Profound Medical's price analysis, check to measure Profound Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Profound Medical is operating at the current time. Most of Profound Medical's value examination focuses on studying past and present price action to predict the probability of Profound Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Profound Medical's price. Additionally, you may evaluate how the addition of Profound Medical to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Stocks Directory Find actively traded stocks across global markets |